Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials

@article{Cai2015ComparisonBP,
  title={Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials},
  author={Panpan Cai and Xiaohong Tang and Wei Qin and Ling Fei Ji and Zi Li},
  journal={International Urology and Nephrology},
  year={2015},
  volume={48},
  pages={571-584}
}
PurposeThe goal of this systematic review is to evaluate the efficacy and safety of paricalcitol versus active non-selective vitamin D receptor activators (VDRAs) for secondary hyperparathyroidism (SHPT) management in chronic kidney disease (CKD) patients.MethodsPubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), clinicaltrials.gov (inception to September 2015), and ASN Web site were searched for relevant studies. A meta-analysis of randomized controlled trials (RCTs) and… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 55 REFERENCES

A randomised clinical study of alfacalcidol and paricalcitol

D Hansen
  • Dan Med J 59:B4400
  • 2012
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Alfacalcidol and paricalcitol have similar effects on left ventricular hypertrophy

M Nikodimopoulou, S Liakos, S Kapoulas
  • Nephrol Dial Transplant
  • 2012
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL